

Hepatitis C virus infection in health-care settings: Medical and ethical implications

Francisco Javier Bosques-Padilla,* Genaro Vázquez-Elizondo,* Ana Villaseñor-Todd,*
Elvira Garza-González,** José Alberto Gonzalez-Gonzalez,* Héctor Jesús Maldonado-Garza*

* Facultad de Medicina y Centro Regional para el Estudio de Enfermedades Digestivas. (CREED) Hospital Universitario "Dr. José Eleuterio González" UANL.

** Departamento de Microbiología, Facultad de Medicina. Monterrey, N.L. México.

ABSTRACT

Hepatitis C is a major public health issue. It infects about 200 million people worldwide and is a major cause of chronic liver disease. Its transmission in medical facilities is a topic of increased concern, as outbreaks of the disease had raised the attention of media and medical authorities. To date, evidence suggests that infection from in which a health-care worker is involved is mostly result of bad injecting practices as well as the result of shared medical devices. Furthermore, the infection caused by physicians is rare and very few well documented cases exist on the literature. Among countries, different definitions and legislation exist, in that mode that the responsibility of this issue almost is a an obligation of individual institutions. Nonetheless, Hepatitis C virus transmission in medical facilities is an important source of new cases, and as treatments options are very limited, its recommendable that institutions as well as governments implement policies to avoid Hepatitis C spread in a almost fully preventable setting.

Key words. Health care worker. Hepatitis C. Prophylaxis. Ethics. Percutaneous wound.

INTRODUCTION

Hepatitis C virus (HCV) infection is a global public health problem. Although the virus was first cloned in 1989 and its true behavior is not known, it is estimated that it causes infection in about 170 to 200 million people worldwide.^{1, 2} An asymptomatic acute phase of infection fails to clear the virus in a majority of patients (about 80%) and consequently, progression to a chronic infection explains the nature of the disease, of which the long-term course is not completely understood.¹ Infection rate disease has a great variability in different countries, as low as 0.1% in Canada and as high as 18.1% en Egypt according to data from World Health Organization (WHO). In Latin America, Bolivia has the highest rate of infection (11.2%), followed by Suriname

(5.5%) and Trinidad and Tobago (4.9%); on the contrary the lowest rates have been reported in Dominican Republic (2.4%), Perú (1.6%) and México (0.7%).^{1, 3} Evidence from different series have defined certain groups at higher risk for HCV infection such as patients transfused with blood products before 1992 or coagulation concentrates before 1987, hemophiliacs, injecting drug users, patients in hemodialysis centers, people administrating or receiving acupuncture and/or tattooing with unsterile devices, patients with multiple sexual contacts and infants born to infected mothers as well as health care workers(HCW).³⁻⁵ Within this later group the estimated prevalence of HCV ranges from 1 to 10%,⁶ and therefore, it is a major concern in infection transmission. As transmission from patient-to-patient and patient-to-HCW in hospital and non-hospital facilities are proven scenarios,⁷⁻²⁴ another less reported and gaining attention is the HCW-to-patient transmission. The risk of transmission by this modality was considered uncommon, with approximately 200 cases reported in the literature^{25, 26} with only a few properly documented. Nonetheless, this issue has raised attention because of the ethical, medical and legal implications as represented by cases of Anesthesiologists,²⁷⁻³⁰ Gastroenterologists^{17,31} and Surgeons.³²⁻³⁴ With very few effective treatment modalities available, avoidance of infection remains the

Correspondence and reprint request: Francisco Javier Bosques-Padilla, M.D.
Facultad de Medicina y Centro Regional para el
Estudio de Enfermedades Digestivas, (CREED).
Hospital Universitario "Dr. Jose Eleuterio González" UANL.
Monterrey, N.L. México.
Madero y Gonzalitos S/N Col. Mitras Centro, Monterrey, N.L. México.
Phone: (52)(81)83333664, fax: (52)(81)83486068.
E-mail: fbosques58@hotmail.com

Manuscript received: March 20, 2010.

Manuscript accepted: April 20, 2010.

main strategy to prevent one of the main causes of liver disease world wide.³⁵

DEFINITION OF EXPOSURE AND TRANSMISSION MODES

According to the Centers for Disease Control and Prevention, (CDC) an exposure event with risk of HCV infection is defined as a percutaneous injury (needle-stick or cut with a sharp object) contaminated with blood or another fluid as well as contact with a mucous membrane or non-intact skin with blood, tissue or other body fluid that is potentially infectious (semen, vaginal secretions, cerebrospinal, synovial, pleural, peritoneal, pericardial, and amniotic fluids; however feces, nasal secretions, saliva, sputum, sweat, tears, urine, and vomit are not included unless they contain visible blood).³⁶ Nonetheless, this definition does not include the risk of transmission from performing an exposure-prone procedure (EPP). The definition of these procedures is variable in the literature, and probably the most accurate is that states invasive procedures where there is risk that injury to the HCW may result in the expose of the patient's open tissues to the blood of the HCW (so called bleed-back).³⁷ This issue is best addressed on the consensus published by Dr. Angelique M Reitsma, *et al*,³⁸ which defined risk categories and evidence decision-making for HCW infected with HCV (Table 1).

Although the above definitions explain the patient-to-HCW and HCW-to-patient transmission, the last group that should be considered is the patient-to-patient infection in medical facilities. This mode of transmission is commonly manifested as outbreaks, and is usually explained by inadequate infection control practices (such as bad injection practices or sharing of medical devices). The typical scenarios are hemodialysis wards, oncology units, long-term stay facilities and outpatient clinics.^{26, 39-46}

EPIDEMIOLOGY AND RISK FACTORS OF INFECTION IN MEDICAL FACILITIES

Data regarding the prevalence of HCV in HCW is scarce and a numerical risk is difficult to estimate. A study performed in Mexico City on risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care found a prevalence of 0.8% (one positive case).⁴⁷ Similar results were shown in other series⁴⁸⁻⁵³ but other studies found higher rates, ranging from 1.6 to 4%.⁵⁴⁻⁵⁶ In spite of these figures, the transmission from a

HCW-to-patient is still considered rare as only few cases had been adequately documented in literature; nonetheless, the consequences of this are devastating.^{25,27,57} HCV transmission in medical settings is mainly percutaneous, by means of contact with contaminated blood, sharing of infected needles or devices^{1,57,58} However, HCV is not effectively spread through occupational exposures of blood, such as accidental percutaneous injury, with a calculated risk of 1.8% (range 0 - 7%).⁵⁹ In addition, not all injuries seem to confer the same risk. In a multivariate analysis of a prospective case-control study, the factors associated to HCV transmission were the use of hollow-borne suture needles, placement in a patient artery or vein, the severity (depth) of the injury⁶⁰ as well as viremia detected by polymerase chain reaction.⁶¹ However, an identifiable high risk groups have been described. For example, data from the National Surveillance System for Healthcare Workers in United States have identified nurses as the group which accounted for the higher number of exposition events (41%), followed by physicians (31%). This is partly explained since nurses usually outnumber physicians in a hospital.¹⁵ Furthermore, although frequently underreported, the highest risk groups by occupation are those related to surgical and gynecological staff, as well as nursing and medical students, most lesions occurring within the operating room.^{60, 62-70}

On the other hand, its estimated that approximately 2 million of HCV infections annually are acquired from contaminated syringes in medical settings.⁷¹ The estimation is raised to 4.7 million when considering medical facilities in developing countries.⁷² This is an almost fully preventable route of transmission, with high economic cost and significant morbidity and mortality, usually affecting susceptible or debilitated populations.^{8, 19, 73, 74}

STRATEGIES TO PREVENT HCV TRANSMISSION IN HEALTH CARE SETTINGS

Due to few treatments available, the absence of effective post-exposure prophylaxis regimen and the high proportion of patients developing a chronic infection, prevention stands as the main measure in precluding HCV infection.^{23, 26, 75}

Measures previous to HCV exposure

The major goal of a preventive program is to trying to identify patients at risk for chronic HCV

Table 1. Risk categorization for an exposure-prone procedure (EPP) and recommended conduct in HCV infected HCW. (adapted from Reitsma A, *et al.*).³⁸

Category	Examples
Category I Minimal risk of viral transmission (No emergency or violence prone settings)	- Regular history-taking and/or physical examinations, including gloved oral examination with a mirror and/or tongue depressor. - Routine rectal or vaginal examinations. - Minor surface suturing. - Elective peripheral phlebotomy. - Sigmoidoscopy and colonoscopy. - Hands-off supervision during surgical procedures and computer-aided remote or robotic surgical procedures. - Psychiatric evaluations.
Category II Viral transmission risk possible but unlikely	Procedures that warrant general attention. - Locally anesthetized ophthalmologic surgery. - Minor local procedures under local anesthesia. - Percutaneous cardiological procedures. - Percutaneous and other minor orthopedic procedures. - Subcutaneous pacemaker implantation. - Bronchoscopy. - Insertion and maintenance of epidural and spinal anesthesia. - Minor gynecological procedures. - Male urological procedures. - Upper gastrointestinal tract endoscopic procedures. - Minor vascular procedures. - Amputations, including major limbs and minor amputations. - Mamma augmentation. - Minimum-exposure plastic surgical procedures. - Thyroidectomy and/or biopsy. - Endoscopic ear, nose, and throat surgery. Procedures that warrant special attention - Assistance with at uncomplicated vaginal delivery (except episiotomy, category III). - Laparoscopic procedures (conversion to open surgery warrants category III). - Thoracoscopic procedures (conversion to open surgery warrants category III). - Nasal endoscopic procedures (conversion to open surgery warrants category III). - Routine arthroscopic procedures (open-joint or power instruments used requires category III classification). - Plastic surgery (major bones or vasculature and/or deep body cavities requires category III classification). - Insertion of, maintenance of, and drug administration into arterial and central venous lines. - Endotracheal intubation and use of laryngeal mask.
Category III Exposure-prone procedures (EPP)	- Anesthesiology: Administration of general anesthesia, preparation of narcotic drugs, placement of venous and arterial catheters, intubation of patients, and artificial respiration. - Cardiothoracic surgery: valve replacement, coronary artery bypass. - grafting, other bypass surgery, orthoptic heart transplantation, repair of congenital heart defects, thymectomy, open-lung biopsy. - Open extensive head and neck surgery involving bones. - Oncological procedures and amputations. - Neurosurgery Craniotomy and intracranial procedures and open-spine surgery. - Nonelective procedures performed in the emergency department. - Open resuscitation efforts, vaginal or rectal examination in presence of pelvic fracture, deep suturing to arrest hemorrhage, and internal cardiac massage. - Surgery involving transvaginal obstetrical and gynecological procedures. involving hand-guided sharps. - Plastic surgery Extensive cosmetic procedures. - Psychiatric evaluations and care of violent and/or biting patients. - Transplantation surgery. - Trauma surgery (open head injuries, extensive soft-tissue trauma, and ophthalmic trauma). - Interactions with patients in situations during which risk of biting of physician is significant. - Any open surgical procedure of 13 h in duration, probably necessitating glove change.
Category	Viral Load
	Detectable but < 10 ⁶ virions/mL
	High viral load (≥10 ⁶ virions/mL)
I	No restrictions
II	No restrictions
III	Do not attempt

infection. Currently, based on epidemiological data the indications for routine HCV testing is recommended in patients with history of injected illegal drug use, transfusion of blood before 1992 or blood products before 1987, in hemodialysis or with evidence of liver disease. For medical staff, since HCW-to-patient transmission is rare,²⁶ the current United States recommendation is to screen staff that has been exposed to blood from a HCV-positive patient.⁷⁶ On the contrary, several health systems in Europe propose that prevention should be based on the screening for antibodies to HCV of all HCW who perform EPPs and, if positive, proceed to perform polymerase chain reaction testing for hepatitis C ribonucleic acid, to further determine their infectivity. This procedure is repeated after every exposure event.²⁵

Other general useful measures are the Universal Measures (developed in response to HIV/AIDS epidemic)⁷⁷ and Body Substance Isolation⁷⁸ recommendations. These guidelines assume that every patient is a possible source of infection until proven the contrary.²³ A comprehensive guideline of recommendations has been published by the CDC and is available elsewhere (Table 2).⁷⁹ These directives should be supported by administrative, financial and specialized human resources, as well as educational programs directed to every level of attention (medical students, nurses, physicians, volunteers, social workers, etc) held in the medical facility addressed.^{75, 80} These recommendations apply for prevention of transmission between patients and HCW as they intend to prevent any contact with HCV.

Measures posterior to a HCV exposure event

Although several guidelines exist for the management of a HCW exposure, every institution is responsible for each preventive medicine policy.⁸¹ Once the exposition has occurred, aid should be given as prompt as possible to the exposed worker. This implies a reporting system not only to identify this kind of lesions, but also to recognize hazards in workplaces in order to perform preventive measures. These systems should not only give ready access to experts in the field but also to protect the confidentiality of the affected HCW.^{23, 81}

First aid care should be offered in every case as soon as possible. Percutaneous injuries should be washed by soap and water as well as vigorously flushed with water. Contact with intact skin requires wash with soap and water. As at least one case had

been documented by conjunctival inoculation⁸² eyes should be irrigated with clean water, saline or sterile irrigants. There is no evidence that supports the use of antiseptics/disinfectants to reduce HCV transmission, but their use is not contraindicated; but the use of caustic agents or injection of antiseptics/disinfectants is not recommended.^{23, 83, 84}

Next step is to assess the degree of exposure should be addressed. Figure 1 shows a suggested algorithm in classifying an exposure event. The highest risk patient for contagion is those who have HCV viremia detected by third generation PCR.⁶¹ This test is almost 100% sensitive to detect seroconversion 4 to 10 weeks after infection. Delayed detection and false-negative results are seen in patients with renal failure, HIV infection and extra-hepatic manifestations of HCV infection, therefore special emphasis on follow up should be guaranteed when considering patients in these groups.⁸⁵ For every case, both HCW and patient baseline HBV, HCV and HIV status should be tested, since post-exposure prophylaxis exist for HIV and HBV exposures.⁸⁶ For vaccinated or naturally immunized HCW, testing for HVB superficial antigen could be spared. When source of infection cannot be tested or refuse to be tested, it should be considered as infected.⁸⁴ Furthermore, CDC recommends that following a occupational HCV exposure the following measures should be taken:^{59, 76}

- For the source, perform testing for anti-HCV
- For the HCW exposed to a HCV-positive source:
 - Perform baseline testing for anti-HCV and ALT activity
 - Follow-up testing (4-6 months) for anti-HCV and ALT
 - Confirm diagnosis with either HCV-RNA or anti-HCV RIBA™ (recombinant immunoblot assay).

There is no recommendation for activity restriction during post-exposure follow-up period, until there is a proven infection. In this regard, the consensus for HCV infected HCW presented on table 1 could be a useful guide for providing medical attention.³⁸ Nonetheless, in Germany, there is no activity restriction for HCW HCV-positive until viral load of 1×10^3 IU/mL.²⁵ Other countries in Europe follow similar conducts.^{84, 87} It is a duty of the HCW that is known to have HCV infection to comply with the working restrictions as well as regular evaluation designed by the Preventive Medicine Department of each institution.

Table 2. Standard precautions for the care of all patients in all healthcare settings.⁷⁹

<i>Component</i>	<i>Recommendations</i>
Hand hygiene	After touching blood, body fluids, secretions, excretions, contaminated items; immediately after removing gloves; between patient contacts .
Personal protective equipment (PPE)	
Gloves	For touching blood, body fluids, secretions, excretions, contaminated items; for touching mucous membranes and non-intact skin.
Gown	During procedures and patient-care activities when contact of clothing/exposed skin with blood/body fluids, secretions, and excretions is anticipated.
Mask, eye protection (goggles), face shield*	During procedures and patient-care activities likely to generate splashes or sprays of blood, body fluids, secretions, especially suctioning, endotracheal intubation
Soiled patient-care equipment	Handle in a manner that prevents transfer of microorganisms to others and to the environment; wear gloves if visibly contaminated; perform hand hygiene.
Environmental control	Develop procedures for routine care, cleaning, and disinfection of environmental surfaces, especially frequently touched surfaces in patient-care areas.
Textiles and laundry	Handle in a manner that prevents transfer of microorganisms to others and to the environment.
Needles and other sharps	Do not recap, bend, break, or hand-manipulate used needles; if recapping is required, use a one-handed scoop technique only; use safety features when available; place used sharps in puncture-resistant container.
Patient resuscitation	Use mouthpiece, resuscitation bag, other ventilation devices to prevent contact with mouth and oral secretions.
Patient placement	Prioritize for single-patient room if patient is at increased risk of transmission, is likely to contaminate the environment, does not maintain appropriate hygiene, or is at increased risk of acquiring infection or developing adverse outcome following infection.
Respiratory hygiene/cough etiquette (source containment of infectious respiratory secretions in symptomatic patients, beginning at initial point of encounter e.g., triage and reception areas in emergency departments and physician offices)	Instruct symptomatic persons to cover mouth/nose when sneezing/coughing; use tissues and dispose in no-touch receptacle; observe hand hygiene after soiling of hands with respiratory secretions; wear surgical mask if tolerated or maintain spatial separation, >3 feet if possible.

* During aerosol-generating procedures on patients with suspected or proven infections transmitted by respiratory aerosols (e.g., SARS), wear a fit-tested N95 or higher respirator in addition to gloves, gown, and face/eye protection.




Figure 1. Algorithm suggested to evaluate and management in a HCV exposure. (Adapted of data from ^{60, 84, 92}). HBV: Hepatitis B virus; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus, HCW: Health-care worker; LFT: liver function tests, RNA: ribonucleic acid; PCR: polymerase chain reaction.

CONCLUSIONS

Until new anti-HCV therapeutic options such as new HCV serine protease and polymerase inhibitors,^{88, 89} neutralizing antibodies to hepatitis C virus^{2, 90} or an anti-HCV vaccine are available,⁹¹ the main opportunity in avoiding liver disease from HCV remains the prevention of infection. While public health programs focus on identify population at risk, prevention of HCV spread in medical facilities represents one of the most important national public health tasks, especially in developing countries.

REFERENCES

1. Bostan N, Mahmood T. An overview about hepatitis C: A devastating virus. *Crit Rev Microbiol*.
2. Yu MY, Bartosch B, Zhang P, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. *Proc Natl Acad Sci USA* 2004; 101: 7705-10.
3. Global Alert and Response: Hepatitis C. World Health Organization, 2002. (Accessed March 31, 2010, at <http://www.who.int/csr/disease/hepatitis/whocdscrlyo2003/en/index.html>.)
4. Esteban JI, Esteban R, Viladomiu L, et al. Hepatitis C virus antibodies among risk groups in Spain. *Lancet* 1989; 2: 294-7.
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005; 5: 5 8-67.
6. Naoumov NV. Hepatitis C virus infection in Eastern Europe. *J Hepatol* 1999; 31(Suppl. 1): 84-7.
7. Bracho MA, Gosalbes MJ, Blasco D, Moya A, Gonzalez-Candelas F. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit. *J Clin Microbiol* 2005; 43: 2750-5.
8. Mailliard ME, Capadano ME, Hrnicek MJ, Gilroy RK, Gulizia JM. Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C. *Hepatology* 2009; 50: 361-8.
9. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. *Infect Control Hosp Epidemiol* 2005; 26: 752-60.

10. Spada E, Abbate I, Sicurezza E, et al. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit in Italy. *J Med Virol* 2008; 80: 261-7.
11. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. *Ann Intern Med* 2009; 150: 33-9.
12. Castell J, Gutierrez G. [Outbreak of 18 cases of hepatitis C in a hemodialysis unit]. *Gac Sanit* 2005; 19: 214-20.
13. Niu MT, Alter MJ, Kristensen C, Margolis HS. Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. *Am J Kidney Dis* 1992; 19: 345-52.
14. Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. *Ann Intern Med* 2005; 142: 898-902.
15. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. *Gastroenterology* 2009; 136: 1609-17.
16. Summaries for patients. Description of a hepatitis C outbreak in a cancer clinic. *Ann Intern Med* 2005; 142: 138.
17. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic-Nevada, 2007. *MMWR Morb Mortal Wkly Rep* 2008; 57: 513-7.
18. Comstock RD, Mallonee S, Fox JL, et al. A large nosocomial outbreak of hepatitis C and hepatitis B among patients receiving pain remediation treatments. *Infect Control Hosp Epidemiol* 2004; 25: 576-83.
19. Knoll A, Helmig M, Peters O, Jilg W. Hepatitis C virus transmission in a pediatric oncology ward: analysis of an outbreak and review of the literature. *Lab Invest* 2001; 81: 251-62.
20. Styczynski J, Wysocki M, Koltan S, Kurylak A. Epidemiologic aspects and preventive strategy of hepatitis B and C viral infections in children with cancer. *Pediatr Infect Dis J* 2001; 20: 1042-9.
21. Wenzel RP, Edmond MB. Patient-to-patient transmission of hepatitis C virus. *Ann Intern Med* 2005; 142: 940-1.
22. Transmission of hepatitis B and C viruses in outpatient settings—New York, Oklahoma, and Nebraska, 2000-2002. *MMWR Morb Mortal Wkly Rep* 2003; 52: 901-6.
23. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. *Clin Microbiol Rev* 2000; 13: 385-407.
24. Puro V, De Carli G, Scognamiglio P, Porcasi R, Ippolito G. Risk of HIV and other blood-borne infections in the cardiac setting: patient-to-provider and provider-to-patient transmission. *Ann N Y Acad Sci* 2001; 946: 291-309.
25. Raggam RB, Rossmann AM, Salzer HJ, Stauber RE, Kessler HH. Health care worker-to-patient transmission of hepatitis C virus in the health care setting: Many questions and few answers. *J Clin Virol* 2009; 45: 272-5.
26. Alter MJ. Prevention of spread of hepatitis C. *Hepatology* 2002; 36: S93-8.
27. 2.000 años para el anestesista Maeso por contagiar hepatitis C a 275 personas. Asociación Española de Enfermos de Hepatitis C., 2007. (Accessed March 31, 2010, at <http://www.aehc.es/content/view/184/38/>)
28. Cody SH, Nainan OV, Garfein RS, et al. Hepatitis C virus transmission from an anesthesiologist to a patient. *Arch Intern Med* 2002; 162: 345-50.
29. Gutelius B, Perz JF, Parker MM, et al. Multiple Clusters of Hepatitis Virus Infections Associated with Anesthesia for Outpatient Endoscopy Procedures. *Gastroenterology*.
30. Mawdsley J, Teo CG, Kyi M, Anderson M. Anesthetist to patient transmission of hepatitis C virus associated with non exposure-prone procedures. *J Med Virol* 2005; 75: 399-401.
31. Sicot C. [Legal outcome of a case of hepatitis C nosocomial infection]. *Gastroenterol Clin Biol* 2007; 31: 313.
32. Duckworth GJ, Heptonstall J, Aitken C. Transmission of hepatitis C virus from a surgeon to a patient. The Incident Control Team. *Commun Dis Public Health* 1999; 2: 188-92.
33. Ross RS, Steinbruckner B, Bohm S, Viazov S, Jilg W, Roggendorf M. Outcome of an exercise to notify patients treated by a general surgeon infected with the hepatitis C virus. *J Clin Virol* 2008; 41: 314-7.
34. Esteban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. *N Engl J Med* 1996; 334: 555-60.
35. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; 45: 529-38.
36. Alvarado-Ramy F, Beltrami EM. New guidelines for occupational exposure to blood-borne viruses. *Cleve Clin J Med* 2003; 70: 457-65.
37. United Kingdom Department of Health HIV-infected health care workers: Guidance on management and patient notification. 2005. (Accessed April 1, 2010, at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4116415.)
38. Reitsma AM, Cloesen ML, Cunningham M, et al. Infected physicians and invasive procedures: safe practice management. *Clin Infect Dis* 2005; 40: 1665-72.
39. Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR Recomm Rep* 2001; 50: 1-43.
40. Krause G, Trepka MJ, Whisenhunt RS, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. *Infect Control Hosp Epidemiol* 2003; 24: 122-7.
41. Bronowicki JP, Venard V, Botte C, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. *N Engl J Med* 1997; 337: 237-40.
42. Izopet J, Sandres-Saune K, Kamar N, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. *J Med Virol* 2005; 77: 70-6.
43. Quer J, Esteban JI, Sanchez JM, et al. Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning. *Eur J Gastroenterol Hepatol* 2008; 20: 73-8.
44. Silini E, Locasciulli A, Santoleri L, et al. Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome. *Haematologica* 2002; 87: 1200-8.
45. Tallis GF, Ryan GM, Lambert SB, et al. Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules. *J Viral Hepat* 2003; 10: 234-9.
46. Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. *Clin Microbiol Rev* 2003; 16: 546-68.
47. Mendez-Sanchez N, Motola-Kuba D, Zamora-Valdes D, et al. Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. *Ann Hepatol* 2006; 5: 276-80.
48. Villasis-Keever MA, Pena LA, Miranda-Novales G, et al. Prevalence of serological markers against measles, rubella,

- varicella, hepatitis B, hepatitis C, and human immunodeficiency virus among medical residents in Mexico. *Prev Med* 2001; 32: 424-8.
49. Flores-Castaneda MS, Garcia-Mendez BL, Tijerina-Menchaca R. [HCV and HBV seropositivity in university students of the State of Nuevo Leon, Mexico]. *Rev Gastroenterol Mex* 1996; 61: 327-31.
50. Lodi G, Porter SR, Teo CG, Scully C. Prevalence of HCV infection in health care workers of a UK dental hospital. *Br Dent J* 1997; 183: 329-32.
51. Thomas DL, Factor SH, Kelen GD, Washington AS, Taylor E JR, Quinn TC. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. *Arch Intern Med* 1993; 153: 1705-12.
52. Campello C, Majori S, Poli A, Pacini P, Nicolardi L, Pini F. Prevalence of HCV antibodies in health-care workers from northern Italy. *Infection* 1992; 20: 224-6.
53. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. *Intervirology* 2007; 50: 1-8.
54. Catalani C, Biggeri A, Gottard A, Benvenuti M, Frati E, Cecchini C. Prevalence of HCV infection among health care workers in a hospital in central Italy. *Eur J Epidemiol* 2004; 19: 73-7.
55. Vivas Arceo C, Torres Garibay JC, Aguilar Benavides S. [Prevalence of hepatitis B and C virus markers among medical staff at a third-level hospital]. *Rev Gastroenterol Mex* 1997; 62: 108-12.
56. Jindal N, Jindal M, Jilani N, Kar P. Seroprevalence of hepatitis C virus (HCV) in health care workers of a tertiary care centre in New Delhi. *Indian J Med Res* 2006; 123: 179-80.
57. Alter MJ. Transmission of hepatitis C virus—route, dose, and titer. *N Engl J Med* 1994; 330: 784-6.
58. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. *Infect Agents Dis* 1993; 2: 155-66.
59. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. *MMWR Recomm Rep* 2001; 50: 1-52.
60. Yazdanpanah Y, De Carli G, Miguères B, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. *Clin Infect Dis* 2005; 41: 1423-30.
61. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. *BMJ* 1997; 315: 333-7.
62. Patterson JM, Novak CB, Mackinnon SE, Ellis RA. Needlestick injuries among medical students. *Am J Infect Control* 2003; 31: 226-30.
63. Sharma GK, Gilson MM, Nathan H, Makary MA. Needlestick injuries among medical students: incidence and implications. *Acad Med* 2009; 84: 1815-21.
64. Petrucci C, Alvaro R, Cicolini G, Cerone MP, Lancia L. Percutaneous and mucocutaneous exposures in nursing students: an Italian observational study. *J Nurs Scholarsh* 2009; 41: 337-43.
65. Deisenhammer S, Radon K, Nowak D, Reichert J. Needlestick injuries during medical training. *J Hosp Infect* 2006; 63: 263-7.
66. Jepsen MP, Smith E. [Needlestick injuries among medical students at the University of Copenhagen. A questionnaire study in 2001]. *Ugeskr Laeger* 2003; 165: 2275-9.
67. Rosenthal E, Pradier C, Keita-Perse O, Altare J, Dellamonica P, Cassuto JP. Needlestick injuries among French medical students. *JAMA* 1999; 281: 1660.
68. Schmid K, Schwager C, Drexler H. Needlestick injuries and other occupational exposures to body fluids amongst employees and medical students of a German university: incidence and follow-up. *J Hosp Infect* 2007; 65: 124-30.
69. Yang YH, Wu MT, Ho CK, et al. Needlestick/sharps injuries among vocational school nursing students in southern Taiwan. *Am J Infect Control* 2004; 32: 431-5.
70. Makary MA, Al-Attar A, Holzmüller CG, et al. Needlestick injuries among surgeons in training. *N Engl J Med* 2007; 356: 2693-9.
71. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. *Int J STD AIDS* 2004; 15: 7-16.
72. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. *Health Promot Int* 2004; 19: 95-103.
73. Rodriguez-Caravaca G, Villar-Del-Campo MC, Casas-Losada ML, Cava-Valenciano F, Gil-De-Miguel A. [Hepatitis C outbreak in an oncology ward.]. *Enferm Infecc Microbiol Clin* 2009.
74. Thompson ND, Novak RT, Datta D, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. *Infect Control Hosp Epidemiol* 2009; 30: 900-3.
75. MacCannell T, Laramie AK, Gomaa A, Perz JF. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies. *Clin Liver Dis* 14: 23-36, vii.
76. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 1998; 47: 1-39.
77. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR Morb Mortal Wkly Rep* 1988; 37: 377-82, 87-8.
78. Lynch P, Jackson MM, Cummings MJ, Stamm WE. Rethinking the role of isolation practices in the prevention of nosocomial infections. *Ann Intern Med* 1987; 107: 243-6.
79. CDC Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007. Centers for Disease Control and Prevention, 2007. (Accessed March 31, 2010, at <http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html>.)
80. Vaughn TE, McCoy KD, Beekmann SE, Woolson RE, Torner JC, Doebbeling BN. Factors promoting consistent adherence to safe needle precautions among hospital workers. *Infect Control Hosp Epidemiol* 2004; 25: 548-55.
81. The prevention of transmission of blood-borne diseases in the health-care setting. Department of Health and Children - Ireland, 2005. (Accessed April 1, 2010, at http://www.dohc.ie/publications/transmission_of_blood_borne_diseases_2006.html.)
82. Hosoglu S, Celen MK, Akalin S, Geyik MF, Soyoral Y, Kara IH. Transmission of hepatitis C by blood splash into conjunctiva in a nurse. *Am J Infect Control* 2003; 31: 502-4.
83. Pruss-Ustun A, Rapiti E, Hutin Y. Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. *Am J Ind Med* 2005; 48: 482-90.
84. Puro V, De Carli G, Cicalini S, et al. European recommendations for the management of healthcare workers occu-

- pationally exposed to hepatitis B virus and hepatitis C virus. *Euro Surveill* 2005; 10: 260-4.
85. Charles PG, Angus PW, Sasadeusz JJ, Grayson ML. Management of healthcare workers after occupational exposure to hepatitis C virus. *Med J Aust* 2003; 179: 153-7.
 86. Puro V, Cicalini S, De Carli G, Soldani F, Ippolito G. Towards a standard HIV post exposure prophylaxis for healthcare workers in Europe. *Euro Surveill* 2004; 9: 40-3.
 87. Mele A, Ippolito G, Craxi A, et al. Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. *Dig Liver Dis* 2001; 33: 795-802.
 88. Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. *Liver Int* 2009; 29(Suppl.)1: 57-67.
 89. Sheldon J, Barreiro P, Vincent V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. *Expert Opin Investig Drugs* 2007; 16: 1171-81.
 90. Bartosch B, Bukh J, Meunier JC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. *Proc Natl Acad Sci USA* 2003; 100: 14199-204.
 91. Alvarez-Lajonchere L, Duenas-Carrera S. Advances in DNA immunization against hepatitis C virus infection. *Hum Vaccin* 2009; 5: 568-71.
 92. Varghese GM, Abraham OC, Mathai D. Post-exposure prophylaxis for blood borne viral infections in healthcare workers. *Postgrad Med J* 2003; 79: 324-8.